-
Je něco špatně v tomto záznamu ?
Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy
L. Ruzek, T. Konecny, F. Soucek, D. Konecny, L. Mach, SR. Ommen, SL. Kopecky, RA. Nishimura,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2012-08-15 do Před 2 měsíci
Medline Complete (EBSCOhost)
od 2012-09-01 do 2015-07-15
Nursing & Allied Health Database (ProQuest)
od 2012-08-15 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2012-08-15 do Před 2 měsíci
- MeSH
- beta blokátory terapeutické užití MeSH
- dospělí MeSH
- hypertrofická kardiomyopatie komplikace farmakoterapie MeSH
- inhibitory fosfodiesterasy 5 terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- prevalence MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- sexuální dysfunkce fyziologická farmakoterapie epidemiologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment-phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 ± 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000098
- 003
- CZ-PrNML
- 005
- 20160127113947.0
- 007
- ta
- 008
- 160108s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.amjcard.2015.05.022 $2 doi
- 035 __
- $a (PubMed)26141201
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ruzek, Lukas $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic; Department of Anesthesiology and Intensive Care, St. Anne's University Hospital Brno, Brno, Czech Republic.
- 245 10
- $a Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy / $c L. Ruzek, T. Konecny, F. Soucek, D. Konecny, L. Mach, SR. Ommen, SL. Kopecky, RA. Nishimura,
- 520 9_
- $a The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment-phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 ± 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.
- 650 _2
- $a beta blokátory $x terapeutické užití $7 D000319
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a hypertrofická kardiomyopatie $x komplikace $x farmakoterapie $7 D002312
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a inhibitory fosfodiesterasy 5 $x terapeutické užití $7 D058986
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a sexuální dysfunkce fyziologická $x farmakoterapie $x epidemiologie $7 D012735
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Konecny, Tomas $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Electronic address: tomkony@hotmail.com.
- 700 1_
- $a Soucek, Filip $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Konecny, Dana $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Mach, Lukas $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Ommen, Steve R $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota.
- 700 1_
- $a Kopecky, Stephen L $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota.
- 700 1_
- $a Nishimura, Rick A $u Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota.
- 773 0_
- $w MED00000236 $t The American journal of cardiology $x 1879-1913 $g Roč. 116, č. 4 (2015), s. 618-21
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26141201 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160127114112 $b ABA008
- 999 __
- $a ok $b bmc $g 1102379 $s 924304
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 116 $c 4 $d 618-21 $e 20150521 $i 1879-1913 $m The American journal of cardiology $n Am J Cardiol $x MED00000236
- LZP __
- $a Pubmed-20160108
